NO981858L - Fenyletanolamin-forbindelser anvendelige som <beta>3 agonist, fremgangsmÕte for fremstilling av disse og mellomprodukter i fremstilling av dem - Google Patents

Fenyletanolamin-forbindelser anvendelige som <beta>3 agonist, fremgangsmÕte for fremstilling av disse og mellomprodukter i fremstilling av dem

Info

Publication number
NO981858L
NO981858L NO981858A NO981858A NO981858L NO 981858 L NO981858 L NO 981858L NO 981858 A NO981858 A NO 981858A NO 981858 A NO981858 A NO 981858A NO 981858 L NO981858 L NO 981858L
Authority
NO
Norway
Prior art keywords
lower alkoxy
preparation
substituted
intermediates
represents hydrogen
Prior art date
Application number
NO981858A
Other languages
English (en)
Other versions
NO981858D0 (no
Inventor
Susumu Tsuchiya
Nobuyuki Yasuda
Toshifumi Matsumoto
Kozo Hiratsuka
Hiroyuki Iizuka
Atsusi Hukuzaki
Kouichi Matsunaga
Original Assignee
Tokyo Tanabe Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tokyo Tanabe Co filed Critical Tokyo Tanabe Co
Publication of NO981858D0 publication Critical patent/NO981858D0/no
Publication of NO981858L publication Critical patent/NO981858L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/24—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/36—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår fenyletanolaminforbindelser representert ved generelle formel [I]: OH CH¿CH2¿NH-(CH2) [l ] (hvor R, representerer hydrogen eller halogen; R2 representerer hydrogen, hydroksy, lavere alkoksy, lavere alkoksy substituert med en eller to lavere alkoksykarbonyl eller karboksygrupper, lavere alkoksy substituert med lavere alkylaminokarbonyl som kan være substituert med lavere alkoksy, lavere alkoksy substituert med cyklisk aminokarbonyl med 4 til 6 karbonatomer, lavere alkoksykarbonyl eller karboksy; R3 representerer hydrogen, hydroksy, lavere alkoksy eller lavere alkoksy substituert med en eller to lavere alkoksykarbonyl eller karboksygrupper; R2 og R3 kan være bundet til hverandre for å danne metylendioksy substituert med karboksy eller lavere alkoksykarbonyl; og m og n er O eller 1), og deres farmakologisk akseptable salter, som har en sterk p3-adrenergisk stimulerende effekt og høy (53-adrenergisk reseptorselektivitet, så vel som til fremgangsmåter for deres fremstilling og mellomprodukter i deres fremstilling.
NO981858A 1995-10-26 1998-04-24 Fenyletanolamin-forbindelser anvendelige som <beta>3 agonist, fremgangsmÕte for fremstilling av disse og mellomprodukter i fremstilling av dem NO981858L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP27855495 1995-10-26
JP24962296 1996-09-20
PCT/JP1996/003097 WO1997015549A1 (en) 1995-10-26 1996-10-24 PHENYLETHANOLAMINE COMPOUNDS USEFUL AS β3 AGONIST, PROCESS FOR PRODUCING THE SAME, AND INTERMEDIATES IN THE PRODUCTION OF THE SAME

Publications (2)

Publication Number Publication Date
NO981858D0 NO981858D0 (no) 1998-04-24
NO981858L true NO981858L (no) 1998-06-24

Family

ID=26539396

Family Applications (1)

Application Number Title Priority Date Filing Date
NO981858A NO981858L (no) 1995-10-26 1998-04-24 Fenyletanolamin-forbindelser anvendelige som <beta>3 agonist, fremgangsmÕte for fremstilling av disse og mellomprodukter i fremstilling av dem

Country Status (12)

Country Link
US (1) US6069176A (no)
EP (1) EP0940387B1 (no)
JP (1) JP3926390B2 (no)
KR (1) KR100483635B1 (no)
AT (1) ATE239694T1 (no)
AU (1) AU715216B2 (no)
CZ (1) CZ126598A3 (no)
DE (1) DE69628051T2 (no)
ES (1) ES2193266T3 (no)
HU (1) HUP9802318A3 (no)
NO (1) NO981858L (no)
WO (1) WO1997015549A1 (no)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4685201B2 (ja) * 1996-08-19 2011-05-18 キッセイ薬品工業株式会社 頻尿および尿失禁の予防・治療剤
WO1998024754A1 (en) * 1996-12-04 1998-06-11 Kureha Kagaku Kogyo Kabushiki Kaisha Cyclopentylamine derivatives, process for the preparation thereof, and bactericides
EP1070046A1 (en) * 1998-04-06 2001-01-24 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
EP0982026B1 (en) * 1998-08-18 2006-05-17 F. Hoffmann-La Roche Ag Use of aryl-cyclohexylamine derivatives in the manufacture of NMDA receptor blockers
DE69931316D1 (de) 1998-08-18 2006-06-22 Hoffmann La Roche Verwendung von Aryl-Cyclohexylamine Derivaten zur Herstellung von NMDA-Rezeptorblockern
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
US20030018061A1 (en) * 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
MXPA02009659A (es) 2000-04-26 2003-03-10 Warner Lambert Co Derivado de ciclohexilamina como subtipo de los antagonistas del receptor selectivo nmda.
JP2003535073A (ja) 2000-06-01 2003-11-25 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー サブタイプ選択性ｎｍｄａレセプター拮抗物質としてのシクロヘキシルアミン誘導体
AU2001263130A1 (en) * 2000-06-06 2001-12-17 Warner Lambert Company Bicyclic cyclohexylamines and their use as nmda receptor antagonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6514991B2 (en) * 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6410734B1 (en) * 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6509358B2 (en) 2000-07-17 2003-01-21 Wyeth Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6458817B1 (en) 2000-07-17 2002-10-01 Wyeth Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US20040018959A1 (en) * 2002-05-02 2004-01-29 Randall S. Hickle System and methods of lipid removal from the body
GB0217211D0 (en) 2002-07-24 2002-09-04 Syngenta Participations Ag Organic compounds
DK1559427T3 (da) 2002-11-07 2011-04-26 Astellas Pharma Inc Lægemiddel til overaktiv blære omfattende eddikesyreanilidderivat som den aktive bestanddel
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
EP1927594A1 (en) * 2003-01-14 2008-06-04 Arena Pharmaceuticals, Inc. 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005042021A2 (de) * 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer
US20050250944A1 (en) * 2004-05-04 2005-11-10 Jian Chen Synthesis and uses of synephrine derivatives
EP1799639B1 (en) * 2004-10-12 2013-09-04 Glenmark Pharmaceuticals S.A. Novel dipeptidyl peptidase iv inhibitors, pharmaceutical compositions containing them, and process for their preparation
EP1806335A4 (en) * 2004-10-20 2008-12-03 Mitsubishi Tanabe Pharma Corp METHOD FOR PRODUCING A PHENYLETHANOLAMINE COMPOUND AND INTERMEDIATE PRODUCTS THEREFOR
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
JPWO2007083640A1 (ja) * 2006-01-18 2009-06-11 杏林製薬株式会社 頻尿及び尿失禁の予防又は治療剤
WO2008024787A1 (en) * 2006-08-23 2008-02-28 Medicinova, Inc. Method of treatment or prophylaxis of depression
KR100821567B1 (ko) 2006-11-01 2008-04-15 한국화학연구원 광학 활성 2-설포닐옥시-1-페닐에탄올 유도체의 제조방법
EP2066619A2 (en) * 2006-11-02 2009-06-10 Arete Therapeutics, INC. Soluble epoxide hydrolase inhibitors
US8217027B2 (en) * 2006-12-21 2012-07-10 Abbott Laboratories Sphingosine-1-phosphate receptor agonist and antagonist compounds
AU2008259841B2 (en) * 2007-05-31 2015-02-05 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
JP2011504471A (ja) * 2007-11-23 2011-02-10 レオ ファーマ アクティーゼルスカブ 疾病処置用の新規環式炭化水素
WO2012000498A1 (en) * 2010-06-30 2012-01-05 Leo Pharma A/S New polymorphic form of a calcimimetic compound
JP5968881B2 (ja) * 2010-06-30 2016-08-10 レオ ファーマ アクティーゼルスカブ カルシウム模倣化合物の新規多形
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
AU2011285928B9 (en) 2010-08-03 2018-08-02 B3Ar Therapeutics, Inc. Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
ES2394349B1 (es) 2012-08-29 2013-11-04 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de agonistas selectivos de receptores beta-3 adrenérgicos para el tratamiento de hipertensión pulmonar
JP6450660B2 (ja) * 2014-08-25 2019-01-09 住友化学株式会社 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法
HK1245117A1 (zh) 2014-12-03 2018-08-24 Velicept Therapeutics, Inc. 使用调节释放索拉贝隆用於下尿路症状的组合物和方法
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
ES2967863T3 (es) 2015-10-23 2024-05-06 B3Ar Therapeutics Inc Ion dipolar de solabegron y usos del mismo
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4940226B1 (no) * 1970-05-02 1974-10-31
US3803232A (en) * 1970-09-30 1974-04-09 Ciba Geigy Corp Arylcarboxamidines
JPS517617B2 (no) * 1972-08-25 1976-03-09
US4350685A (en) * 1981-02-06 1982-09-21 Smithkline Corporation Antiallergic imidodisulfamides
JPS62198639A (ja) * 1986-02-26 1987-09-02 Takasago Corp α−アリ−ルカルボニル誘導体の製造法
US4755505A (en) * 1987-08-18 1988-07-05 American Home Products Corporation 1-[2-(dialkylamino)alkyl]-4,5-dihydro-4-(aryl)-1-benzazocine-2,6(1H,3H)-diones as anti-arrhythmic agents
JPH0819032B2 (ja) * 1987-11-20 1996-02-28 三井東圧化学株式会社 ２−（４−ヒドロキシフェニル）−シクロヘキサノンの製造方法
FR2643076B1 (fr) * 1989-02-14 1991-06-21 Midy Spa Carboxyalkyl-ethers de la 2-amino-7-hydroxytetraline
DE4006937A1 (de) * 1990-03-06 1991-09-12 Basf Ag 4-(4-tert.-butylphenyl)cyclohexylamine und diese enthaltende fungizide
JP2971938B2 (ja) * 1990-11-01 1999-11-08 ダイセル化学工業株式会社 分離剤
GB9107827D0 (en) * 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
JP2932330B2 (ja) * 1991-10-28 1999-08-09 雪印乳業株式会社 含窒素化合物の水素化還元方法
DE4210569A1 (de) * 1992-03-31 1993-10-07 Hoechst Ag Verwendung von substituierten µ-Hydroxyethylaminen als fungizide Wirkstoffe

Also Published As

Publication number Publication date
CZ126598A3 (cs) 1998-09-16
KR19990067089A (ko) 1999-08-16
KR100483635B1 (ko) 2005-12-21
EP0940387A4 (en) 2000-07-05
HUP9802318A3 (en) 2001-04-28
NO981858D0 (no) 1998-04-24
AU715216B2 (en) 2000-01-20
ES2193266T3 (es) 2003-11-01
ATE239694T1 (de) 2003-05-15
EP0940387B1 (en) 2003-05-07
WO1997015549A1 (en) 1997-05-01
US6069176A (en) 2000-05-30
JP3926390B2 (ja) 2007-06-06
DE69628051D1 (de) 2003-06-12
AU7335896A (en) 1997-05-15
DE69628051T2 (de) 2004-02-26
HUP9802318A2 (hu) 1999-08-30
EP0940387A1 (en) 1999-09-08

Similar Documents

Publication Publication Date Title
NO981858L (no) Fenyletanolamin-forbindelser anvendelige som &lt;beta&gt;3 agonist, fremgangsmÕte for fremstilling av disse og mellomprodukter i fremstilling av dem
EP1416933B8 (en) Substituted piperidines as modulators of the melanocortin receptor
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
EA200800886A1 (ru) Способ получения 1-н-имидазо[4,5-с]пиридинов и их аналогов
NO20063501L (no) Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese
MX9701305A (es) Piperidinas sustituidas novedosas utiles para el tratamiento de enfermedades alergicas.
EP1484352A4 (en) THIOEPOXY-BASED POLYMERIZABLE COMPOSITION AND PROCESS FOR PRODUCING SUCH COMPOSITION
NO20061251L (no) Fenyl eller pyridylamidforbindelser som prostaglanding-E2-antagonister
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
NO20023161L (no) Substituerte piperidiner, legemidler inneholdende disse forbindelser og fremgangsmåter for fremstilling av dem
NO20062617L (no) Anvendelse av glukosidase inhibitorer for terapi av mucovisidose
NO20055143L (no) Doseringsformer innbefattende AG013736
PL1742957T3 (pl) Sposób otrzymywania telitromycyny
TW200514781A (en) Novel compounds
TW200606152A (en) Piperidine compound and process for preparing the same
NO20063230L (no) CRF receptorantagonister og fremgangsmater for fremstilling derav
WO2009007536A8 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
MX2009010727A (es) Heterociclos como antagonistas de orexina.
DK1673354T3 (da) Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister
UA95922C2 (en) Glucuronate salt of a piperazine compound
NO944121L (no) Epoksyravsyrederivater
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
NO20044881L (no) Acyl-3-karboksyfenylureaderivater, fremstillingsfremgangsmate og anvendelse derav
NO983831L (no) Nye substituerte N-metyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamider som er anvendbare for behandling av allergiske sykdommer
BR9806875A (pt) Processo para a preparação de um composto.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application